For research use only. Not for therapeutic Use.
Buformin (Cat.No:I014885) is an oral antidiabetic drug that belongs to the biguanide class. It works by reducing glucose production in the liver and improving insulin sensitivity in the body. Buformin was widely used in the past for the treatment of type 2 diabetes but has since been largely replaced by metformin due to its association with a higher risk of lactic acidosis. It is still available in some countries as a diabetes treatment option.
| Catalog Number | I014885 |
| CAS Number | 692-13-7 |
| Molecular Formula | C₆H₁₅N₅ |
| Purity | ≥95% |
| Target | PI3K/Akt/mTOR |
| IUPAC Name | 2-butyl-1-(diaminomethylidene)guanidine |
| InChI | InChI=1S/C6H15N5/c1-2-3-4-10-6(9)11-5(7)8/h2-4H2,1H3,(H6,7,8,9,10,11) |
| InChIKey | XSEUMFJMFFMCIU-UHFFFAOYSA-N |
| SMILES | CCCCN=C(N)N=C(N)N |
| Reference | [1]. Amanda B Parris, et al. Buformin Inhibits the Stemness of erbB-2-overexpressing Breast Cancer Cells and Premalignant Mammary Tissues of MMTV-erbB-2 Transgenic Mice. J Exp Clin Cancer Res<br>[2]. Jing Li, et al. Buformin Suppresses Proliferation and Invasion via AMPK/S6 Pathway in Cervical Cancer and Synergizes With Paclitaxel. Cancer Biol Ther. 2018 Jun 3;19(6):507-517. |
